Monte Rosa Therapeutics, Inc.
General ticker "GLUE" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $498.1M (TTM average)
Monte Rosa Therapeutics, Inc. follows the US Stock Market performance with the rate: 41.7%.
Estimated limits based on current volatility of 3.4%: low 15.96$, high 17.10$
Factors to consider:
- Total employees count: 133 (+8.1%) as of 2023
- Top business risk factors: Regulatory and compliance, Operational and conduct risks, Geopolitical risks, Cybersecurity threats, Management dependency
- Current price 44.6% above estimated high
- Earnings for 9 months up through Q3 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2024-12-31 to 2026-12-31
- 2024-12-31 to 2025-12-31 estimated range: [5.52$, 11.94$]
- 2025-12-31 to 2026-12-31 estimated range: [4.87$, 10.71$]
Financial Metrics affecting the GLUE estimates:
- Negative: with PPE of -6.9 at the end of fiscal year the price was high
- Negative: negative Operating income
- Positive: 41.86 < Shareholder equity ratio, % of 50.81 <= 63.39
- Positive: Interest expense per share per price, % of 0 <= 0.01
- Positive: -14.38 < Investing cash flow per share per price, % of -8.61
- Positive: 6.82 < Operating cash flow per share per price, % of 8.13
Short-term GLUE quotes
Long-term GLUE plot with estimates
Financial data
| YTD | 2022-12-31 | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Operating Revenue | $0.00MM | $0.00MM | $75.62MM |
| Operating Expenses | $112.38MM | $143.31MM | $156.73MM |
| Operating Income | $-112.38MM | $-143.31MM | $-81.11MM |
| Non-Operating Income | $3.88MM | $8.30MM | $10.98MM |
| Interest Expense | $3.76MM | $0.00MM | $0.00MM |
| R&D Expense | $85.06MM | $105.05MM | $121.56MM |
| Income(Loss) | $-108.50MM | $-135.01MM | $-70.13MM |
| Taxes | $0.00MM | $0.34MM | $2.57MM |
| Profit(Loss)* | $-108.50MM | $-135.35MM | $-72.70MM |
| Stockholders Equity | $271.41MM | $179.25MM | $222.94MM |
| Assets | $342.39MM | $303.75MM | $438.73MM |
| Operating Cash Flow | $-92.47MM | $-43.80MM | $42.00MM |
| Capital expenditure | $12.91MM | $19.04MM | $3.99MM |
| Investing Cash Flow | $-219.22MM | $88.80MM | $-44.45MM |
| Financing Cash Flow | $20.47MM | $27.49MM | $98.89MM |
| Earnings Per Share** | $-2.30 | $-2.63 | $-0.98 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.